AUTHOR=Seyed Jafari S. Morteza , Feldmeyer Laurence , Bossart Simon , Simon Dagmar , Schlapbach Christoph , Borradori Luca 

TITLE=Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid

JOURNAL=Frontiers in Immunology

VOLUME=11

YEAR=2021

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.611549

DOI=10.3389/fimmu.2020.611549

ISSN=1664-3224

ABSTRACT=<p>Bullous pemphigoid (BP) is a blistering autoimmune skin disease. Omalizumab, a monoclonal antibody directed to IgE, showed a beneficial effect in treatment of recalcitrant BP in case series. More recently, dupilumab, an interleukin (IL)-4-receptor alpha antagonist, also showed promising preliminary results. We describe a patient with refractory BP who showed a complete response to a combination therapy with omalizumab and dupilumab.</p>